arrow
Back
A

Aleix Prat

Hospital Clínic de Barcelona

92H-index
1.3KPaper Count
3.6WCitation Count
Published Papers 459
Publication Date
Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer
err2026-08-13
err0
PREAI
errPaul Cottu; Tomas Pascual; Jerôme Lemonnier; Huilin Hu; Estelle Roux; Roisin M. Connolly; Cynthia X. Ma; Antonio C. Wolff; Thayane Crestani; Pablo Tolosa; Juan M. Ferrero-Cafiero; Antonio Mulero-Sánchez; Fernando Salvador; Guillermo Villacampa; Joaquín Gavilá; Thibault de La Motte Rouge; Aleix Prat
errShare
errSave
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial
err2026-04-08
err0
errOAAI
errAlexios Matikas; Evangelos Tzoras; Michail Sarafidis; Emmanouil G. Sifakis; Judith Bjöhle; Elin Barnekow; Sara Margolin; Erika Isaksson-Friman; Luisa Edman Kessler; Athanasios Zouzos; Hemming Johansson; Mats Hellström; Susanne Agartz; Per Grybäck; Dimitrios Salgkamis; Ioannis Zerdes; Kang Wang; Johan Hartman; Balazs Acs; Wenwen Sun; Ceren Boyaci; Guillermo Villacampa; Tomas Pascual; Joaquin Gavila; Aleix Prat; Charles Perou; Yvonne Brandberg; Jonas Bergh; Thomas Hatschek; Theodoros Foukakis
errShare
errSave
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
err2025-12-10
err0
errOAAI
errMarcin Kubeczko; Andrea d’Amico; Olgierd Chrabanski; Daria Handkiewicz-Junak; Anna Polakiewicz-Gilowska; Katarzyna Swiderska; Marta Mianowska-Malec; Aleksandra Lesniak; Barbarba Lanoszka; Natalya Lisovska; Damian Borys; Bartlomiej Pycinski; Ewa Chmielik; Slawomir Blamek; Aleix Prat; Michal Jarzab
errShare
errSave
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy
err2025-11-04
err0
errOAAI
errKazuki Nozawa; Masataka Sawaki; Yukari Uemura; Michiko Tsuneizumi; Toshimi Takano; Naomi Gondo; Fumikata Hara; Michiko Harao; Tatsuya Toyama; Naruto Taira; Ana Vivancos; Charles M. Perou; Esther Sanfeliu; Fara Brasó-Maristany; Joel S. Parker; Wesley Buckingham; Laia Paré; Guillermo Villacampa; Mercedes Marín-Aguilera; Patricia Villagrasa; Aleix Prat; Hiroji Iwata
errShare
errSave
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)
err2025-10-17
err0
errOAAI
errE.L. Mayer; D. Hlauschek; M. Gnant; P.J. O'Brien; M. Bellet-Ezquerra; M.P. Goetz; M. Ruiz-Borrego; A. Chan; K. Clifton; D. Egle; D. Lake; P. Cabrera; T. Mamounas; G. Pristauz-Telsnigg; Z. Dayao; M. Gil Gil; D. Cameron; T. Traina; P.G. Morris; D. Sabanathan; G. Rinnerthaler; J. Meisel; A. Prat; A.C. Wolff; L-M. Tseng; C. Isaacs; C.F. Singer; G. Rubovszky; T. Foukakis; J. Jassem; E.P. Winer; M. Vetter; J. Federmann; O. Metzger; C. Schurmans; E. Gauthier; D.R. Lu; C. Fesl; A. Dueck; A. DeMichele
errShare
errSave
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy
err2025-10-16
err0
errOAAI
errR. Gómez-Bravo; B. Walbaum; M. Bergamino; O. Martínez-Sáez; F. Schettini; E. Seguí; I. García-Fructuoso; T. Pascual; N. Chic; M. González; A. Rodríguez; M. Rey; P. Giménez-Xavier; P. Blasco; O. Castillo; P. Galván; E. Sanfeliu; B. González-Farré; M. Vidal; B. Adamo; F. Brasó-Maristany; A. Prat; M. Muñoz
errShare
errSave
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
err2025-10-08
err0
errOAAI
errShanu Modi; William Jacot; Hiroji Iwata; Yeon Hee Park; Maria Vidal Losada; Wei Li; Junji Tsurutani; Naoto T. Ueno; Khalil Zaman; Aleix Prat; Konstantinos Papazisis; Hope S. Rugo; Toshinari Yamashita; Nadia Harbeck; Seock-Ah Im; Michelino De Laurentiis; Jean-Yves Pierga; Xiaojia Wang; Andrea Gombos; Eriko Tokunaga; Cecilia Orbegoso Aguilar; Lotus Yung; Feng Xiao; Yingkai Cheng; David Cameron
errShare
errSave
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial
err2025-09-30
err0
errOAAI
errE. Seguí; F. Brasó-Maristany; T. Pascual; E. Sanfeliu; I. Victoria; C. Saura; C. Hierro; A. López-González; Y. Izarzugaza; E. Ciruelos; J. Gavilá; F. Racca; J.M. Cejalvo; K. Amillano; L. Paz-Ares; M. Juan; E. Felip; E. Garralda; B. González; A. Arance; J. Martín-Liberal; B. Conte; B. Walbaum; A. Indacochea; O. Castillo; P. Blasco; F. Pardo; Á. Aguirre; V. Sirenko; X. González; P. Galván; A. Vivancos; J.M. Ferrero-Cafiero; A. Mulero-Sánchez; F. Salvador; G. Villacampa; R. Mesía; A. Cervantes; A. Prat; J. Tabernero
errShare
errSave
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer
err2025-09-24
err0
PREAI
errB. Walbaum; O. Martínez-Sáez; F. Brasó-Maristany; E. Seguí; N. Chic; J. Muñoz i Carrillo; J. Antonio Sola; M. Rey; P. Giménez-Xavier; R. Gómez-Bravo; I. García-Fructuoso; T. Pascual; A. Rodriguez-Hernandez; F. Schettini; M. Bergamino; M. González; L. Angelats; B. Adamo; M. Muñoz; E. Sanfeliu; A. Martínez-Pozo; P. Galván; P. Jares; J.A. Puig-Butillé; I. Cebrecos; C. Sánchez; A. Prat; M. Vidal
errShare
errSave
HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy
err2025-09-05
err0
errOAAI
errD. Pesántez; F. Brasó-Maristany; T. Pascual; L. Angelats; A. Indacochea; M. Cuatrecasas; S. López; E. Sanfeliu; G. Fernández-Esparrach; L. Notario; I. Méndez; D. Momblan; L. Candia; I. Macias; A. Prat; T. Sauri
errShare
errSave
Implementation of the precision oncology program in catalonia’s public health system: results, lessons learned, and future prospects
err2025-09-03
err0
errOAAI
errPilar Mur; Anna Pozuelo; Josep Tabernero; Joan Albanell; Beatriz Bellosillo; Francesc Bosch; Javier Briones; Joan Brunet; Dolors Colomer; Montserrat Domènech; Joan Manel Fontanet; Xavier Matias-Guiu; Ramon Salazar; Rosa Maria Vivanco-Hidalgo; Meritxell Mollà; Lucas Moreno; Aleix Prat; Josep Maria Ribera; Ramón Clèries; Alex Guarga; Josep A. Espinàs; Josep Maria Borras
errShare
errSave
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
err2025-09-01
err0
errOAAI
errT. Pascual; G. Villacampa; M. Oliveira; S. Escrivá-de-Romaní; S. Pernas; L. Paré; B. Adamo; E. Martínez; J. Cortés; A. Perelló; M. Galan; M. Melé; L. Villanueva; M. Gonzalez-Rodriguez; P. Tolosa; B. González-Farré; P. Galván; J. Canes; P. Nuciforo; J.M. Ferrero-Cafiero; X. González-Farré; P. Villagrasa; A. Prat; E. Ciruelos
errShare
errSave
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer
err2025-07-01
err1
PREAI
errStecklein, Shane R.; Martin, Miguel; Villacampa, Guillermo; del Monte-Millan, Maria; Yoder, Rachel; Pathak, Harsh; Cobo, Sandra; Braso-Maristany, Fara; Alvarez, Enrique L.; Echavarria, Isabel; Bueno-Muino, Coralia; Jerez, Yolanda; Cebollero, Maria; Bueno, Oscar; Garcia-Saenz, Jose A.; Moreno, Fernando; Gomez, Henry L.; Massarrah, Tatiana; Herrero, Blanca; Pare, Laia; Marin-Aguilera, Mercedes; Buckingham, Wesley; Lopez-Tarruella, Sara; Villagrasa, Patricia; Godwin, Andrew K.; Salgado, Roberto; Prat, Aleix; Sharma, Priyanka
errShare
errSave
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)
err2025-06-26
err0
errOAAI
errMiguel García-Pardo; Marta García de Herreros; Edouard Auclin; Miquel Ferriol-Galmes; Juan Carlos Laguna; Teresa Gorría; Gerard Caravaca; Joan Sart; Víctor Albarrán-Artahona; Rafael López-Castro; Cristina Teixidó; Giancarlo Castellano; Alex Martínez Bedmar; Ainara Arcocha; Laura Alcolea; Manuel Jiménez; Mario Bernabeu; David Delgado-Cano; Alejandro Navarro; Aleix Prat; Noemí Reguart; Javier Elio; Pilar Garrido; Natasha B. Leighl; Benjamin Besse; Laura Mezquita
errShare
errSave
Corrigendum to “Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors” [Eur. Urol. Open Sci. 70 (2024) 86–90]
err2025-06-04
err0
errOAAI
errMarta Garcia de Herreros; Natalia Jiménez; Leonardo Rodríguez-Carunchio; Eva Lillo; Mercedes Marín-Aguilera; Laura Ferrer-Mileo; Caterina Aversa; Samuel García-Esteve; Joan Padrosa; Isabel Trias; Laia Fernández-Mañas; Albert Font; Isabel Chirivella; Mariona Figols; Miguel Ángel Climent; Aleix Prat; Òscar Reig; Begoña Mellado
errShare
errSave
Impact of fertility preservation protocols on breast cancer gene expression: preliminary results
err2025-06-01
err0
errOAAI
errBarral, Y.; Capo, A. Borras; Braso-Maristany, F.; Ruche, N. Chic; Justo, M. Mendez; Ganau, S.; Gonzalez-Farre, B.; Casals, G.; Civico, S.; Salvador, C.; Galvan, P.; Adamo, B.; Vidal, M.; Prat, A.; Trullas, D. Manau
errShare
errSave
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]
err2025-05-01
err0
PREAI
errNatalia Jiménez; Marta Garcia de Herreros; Òscar Reig; Mercedes Marín-Aguilera; Caterina Aversa; Laura Ferrer-Mileo; Samuel García-Esteve; Leonardo Rodríguez-Carunchio; Isabel Trias; Albert Font; Alejo Rodriguez-Vida; Miguel Ángel Climent; Sara Cros; Isabel Chirivella; Montserrat Domènech; Mariona Figols; Joan Carles; Cristina Suárez; Daniel Herrero Rivera; Enrique González-Billalabeitia; Claudia Cívico; Núria Sala-González; Vicenç Ruiz de Porras; Maria J. Ribal; Aleix Prat; Begoña Mellado
errShare
errSave
Correlation of the HER2DX Genomic Test withPathologic Features in Early-Stage HER2+BreastCancer
err2025-03-01
err0
PREAI
errSanfeliu, Esther; Martinez-Romero, Anabel; Marin-Aguilera, Mercedes; Gonzalez-Farre, Blanca; Galvan, Patricia; Infantes, Angela Aguirre; Alarcon, Valeria Sirenko; Blasco, Paula; Castillo, Oleguer; Hernandez-Illan, Eva; Jares, Pedro; Puig-Butille, Joan Anton; Martinez, Antonio; Munoz, Montserrat; Losada, MariaVidal; Pascual, Tomas; Martinez, Olga; Solis, Elia Segui; Garcia-Fructuoso, Isabel; Cejalvo, Juan Miguel; Ciruelos, Eva; Brunet, Laia Pare; Vivancos, Ana; Villagrasa, Patricia; Buckingham, Wesley; Parker, Joel; Braso-Maristany, Fara; Prat, Aleix
errShare
errSave
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
err2025-02-24
err0
PREAI
errPotrony, Miriam; Morales-Romero, Blai; Moreno, Lorena; Pastor, Belen; Grau, Elia; Badenas, Celia; Villanueva-Canas, Jose Luis; Montalban-Casafont, Aina; Arnau-Collell, Coral; Ramon y Cajal, Teresa; Manrique, Isabel Aragon; Salas, Pilar Carrasco; Puig, Susana; Aguilera, Paula; Alonso, Inmaculada; Cebrecos, Isaac; Gonzalez-Bosquet, Eduardo; Mellado, Begona; Ferrer-Mileo, Laura; Rodriguez-Hernandez, Adela; Prat, Aleix; Munoz, Montserrat; Gaba, Lydia; Adamo, Barbara; Oriola, Josep; Sanchez, Aurora; Puig-Butille, Joan Anton
errShare
errSave
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN
err2025-02-14
err0
errOAAI
errSchmidt, Gilda; Gluz, Oleg; Christgen, Matthias; Reinisch, Mattea; Kuemmel, Sherko; Nitz, Ulrike; Braun, Michael; Aktas, Bahriye; Luedtke-Heckenkamp, Kerstin; Forstbauer, Helmut; Grischke, Eva-Maria; Schumacher, Claudia; Mahlberg, Rolf; Malter, Wolfram; Reimer, Toralf; Nuding, Benno; Stefek, Andrea; Wuerstlein, Rachel; Graeser, Monika; Jozwiak, Katarzyna; Burmeister, Sandy; zu Eulenburg, Christine; Lauseker, Michael; Kolberg-Liedtke, Cornelia; Prat, Aleix; Schmid, Peter; Baehner, Rick; Kreipe, Hans Heinrich; Solomayer, Erich-Franz; Harbeck, Nadia; West German Study Grp Investigators
errShare
errSave